Stock Scorecard
Stock Summary for Altimmune Inc (ALT) - $5.60 as of 3/28/2025 7:13:15 PM EST
Total Score
8 out of 30
Safety Score
30 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for ALT
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for ALT
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for ALT
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for ALT
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for ALT (30 out of 100)
| Stock Price Rating (Max of 10) | 4 |
| Historical Stock Price Rating (Max of 10) | 4 |
| Stock Price Trend (Max of 10) | 2 |
| Book Value (Max of 10) | 2 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for ALT
Financial Details for ALT
Company Overview |
|
|---|---|
| Ticker | ALT |
| Company Name | Altimmune Inc |
| Country | USA |
| Description | Altimmune, Inc., a clinical-stage biopharmaceutical company, focuses on the development of intranasal vaccines, immunomodulatory therapies, and treatments for liver disease. The company is headquartered in Gaithersburg, Maryland. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 12/31/2024 |
| Next Earnings Date | 5/7/2025 |
Stock Price History |
|
| Last Day Price | 5.60 |
| Price 4 Years Ago | 9.16 |
| Last Day Price Updated | 3/28/2025 7:13:15 PM EST |
| Last Day Volume | 1,624,675 |
| Average Daily Volume | 2,899,711 |
| 52-Week High | 11.16 |
| 52-Week Low | 5.14 |
| Last Price to 52 Week Low | 8.95% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 37.01 |
| Sector PE | 40.10 |
| 5-Year Average PE | -6.45 |
| Free Cash Flow Ratio | 3.09 |
| Industry Free Cash Flow Ratio | 11.91 |
| Sector Free Cash Flow Ratio | 47.05 |
| Current Ratio Most Recent Quarter | 16.87 |
| Total Cash Per Share | 1.81 |
| Book Value Per Share Most Recent Quarter | 1.71 |
| Price to Book Ratio | 3.47 |
| Industry Price to Book Ratio | 8.86 |
| Sector Price to Book Ratio | 21.92 |
| Price to Sales Ratio Twelve Trailing Months | 21,448.31 |
| Industry Price to Sales Ratio Twelve Trailing Months | 88.85 |
| Sector Price to Sales Ratio Twelve Trailing Months | 27.78 |
| Analyst Buy Ratings | 5 |
| Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
| Total Shares Outstanding | 77,014,000 |
| Market Capitalization | 431,278,400 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | 1/20/2017 |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 873.0087 |
| Total Years Dividend Increasing | 0 |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -4.41% |
| Reported EPS 12 Trailing Months | -1.34 |
| Reported EPS Past Year | -1.34 |
| Reported EPS Prior Year | -1.44 |
| Net Income Twelve Trailing Months | -103,520,000 |
| Net Income Past Year | -88,447,000 |
| Net Income Prior Year | -84,713,000 |
| Quarterly Revenue Growth YOY | -86.50% |
| 5-Year Revenue Growth | -46.77% |
| Operating Margin Twelve Trailing Months | -497,320.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 139,380,000 |
| Total Cash Past Year | 197,815,000 |
| Total Cash Prior Year | 184,880,000 |
| Net Cash Position Most Recent Quarter | 135,075,000 |
| Net Cash Position Past Year | 193,234,000 |
| Long Term Debt Past Year | 4,581,000 |
| Long Term Debt Prior Year | 4,581,000 |
| Total Debt Most Recent Quarter | 4,305,000 |
| Equity to Debt Ratio Past Year | 0.98 |
| Equity to Debt Ratio Most Recent Quarter | 0.97 |
| Total Stockholder Equity Past Year | 194,099,000 |
| Total Stockholder Equity Prior Year | 185,293,000 |
| Total Stockholder Equity Most Recent Quarter | 133,377,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -78,116,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -1.01 |
| Free Cash Flow Past Year | -75,857,000 |
| Free Cash Flow Prior Year | -62,712,000 |
Options |
|
| Put/Call Ratio | 0.66 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.16 |
| MACD Signal | -0.22 |
| 20-Day Bollinger Lower Band | 4.94 |
| 20-Day Bollinger Middle Band | 7.13 |
| 20-Day Bollinger Upper Band | 9.31 |
| Beta | 0.86 |
| RSI | 42.97 |
| 50-Day SMA | 7.04 |
| 150-Day SMA | 8.02 |
| 200-Day SMA | 8.50 |
System |
|
| Modified | 3/28/2025 5:14:12 PM EST |